BPJS Kesehatan said that patients with metastatic colorectal cancer will still receive the best treatment. As the two colorectal cancer chemotherapy drugs - Bevacizumab and Cetuximab - are removed from JKN-KIS coverage, those patients will get substitution drugs. BPJS Kesehatan President Director Fachmi Indris said that the removal of the two drugs from the JKN-KIS coverage does not mean that the patients will stop getting the treatment.
He said those patients will receive the same chemotherapy usingsubstitution drugs. 28 February 2019.
Jun 16, 2009 - Tetapi kenapa ya, saat pewawancara bertanya, 'Berapa gaji Anda di tempat. Bila harus me-mark up gaji, berapa nilai yang pantas Anda sebutkan? Gaji, arahkan negosiasi untuk menanyakan mengapa Anda harus digaji.